Raptor Pharmaceutical Meets Primary Endpoint in Its Phase 3 Clinical Trial of DR Cysteamine for Nephropathic Cystinosis - Drugs.com MedNews
Links shared publicly online about this topic.
- 116total visits
Raptor Pharmaceutical Meets Primary Endpoint in Its Phase 3 Clinical Trial of DR Cysteamine for Nephropathic Cystinosis - Drugs.com MedNews
Raptor Pharmaceutical Corp. ( Raptor or the Company ) (Nasdaq RPTP) today announced that its Phase 3 clinical trial of Delayed Release or DR Cysteamine, known a
View full resource at drugs.com
Tags: Drug, Pharma, Phase 3 Clinical Trial, Clinical Trial
Most Recently Shared on July 27, 2011 at 2:09 pm By:
Raptor Pharmaceutical Meets Primary Endpoint in Its Phase 3 Clinical Trial of DR Cysteamine for Nephropath... http://bit.ly/nz8t6e #drug
Advertisement
